Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis

Cancer Research

Volumn 60, Issue 24, 2000, Pages 6921-6926

  Ando, Yuichi ^a   Saka, Hideo ^b   Ando, Maki ^a   Sawa, Toshiyuki ^c   Muro, Kei ^d   Ueoka, Hiroshi ^e   Yokoyama, Akira ^f   Saitoh, Soh ^g   Shimokata, Kaoru ^h   Hasegawa, Yoshinori ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^c Gifu Municipal Hospital   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^f NIIGATA CANCER CENTER HOSPITAL   (Japan)

^g AOMORI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^h NAGOYA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; GLUCURONOSYLTRANSFERASE; IRINOTECAN;

ADULT; AGED; ARTICLE; CANCER; CASE CONTROL STUDY; CONTROLLED STUDY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DETOXIFICATION; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LEUKOPENIA; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0034671387     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
2. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer
3. Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter phase III study
4. Phase I study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer
5. Questions raised over release of side-effects data in Japan
6. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11
7. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats
8. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
9. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin
10. A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini
11. The UDP glycosyltransferase gene superfamily: Recommended nomenclature update based on evolutionary divergence
12. Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation
13. Genetic predisposition to the metabolism of irinotecan (CPT-II): Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
14. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism
15. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan
16. Bilirubin metabolism and hyperbilirubinemia
17. Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome
18. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome
19. The UGT1A1*28 allele is relatively rare in a Japanese population
20. Neonatal hyperbilirubinemia and mutation of the bilirubin uridine transferase gene: A common missense mutation among Japanese, Koreans and Chinese
21. Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism
22. Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome
23. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism?
24. Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP-glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II
25. Criteria for the evaluation of the clinical effects of solid cancer chemotherapy
26. Identification of defect in the genes for bilirubin UDP-glucuronosyltransferase in a patient with Crigler-Najjar syndrome type II
27. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity
28. Genetic polymorphism of thiopurine S-methyltransferase: Clinical importance and molecular mechanisms
29. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus
30. Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: Identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue
31. Severe CPT-11 toxicity in patients with Gilbert's syndrome: Two case reports